Evommune, Inc./$EVMN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Evommune, Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Ticker

$EVMN
Sector
Health

Primary listing

NYSE

Employees

48
Headquarters
Palo Alto, United States
Website
www.evommune.com

Evommune, Inc. Metrics

BasicAdvanced
$405m
-
-$5.36
-
-

What the Analysts think about Evommune, Inc.

Analyst ratings (Buy, Hold, Sell) for Evommune, Inc. stock.

Evommune, Inc. Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37bn
-39.75%
Net income
$45bn
107.52%
Profit margin
37.65%
6.78%

Evommune, Inc. Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.